Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

AR (Androgen receptor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	enzalutamide Resistant: A2 - Guideline enzalutamide Resistant : A2	enzalutamide Resistant: A2 - Guideline enzalutamide Resistant : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
AR amplification	Prostate Cancer	AR amplification	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
AR amplification	Prostate Cancer	AR amplification	Prostate Cancer	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B
AR positive + ER positive	HER2 Negative Breast Cancer	AR positive + ER positive	HER2 Negative Breast Cancer	enobosarm Sensitive: B - Late Trials enobosarm Sensitive : B	enobosarm Sensitive: B - Late Trials enobosarm Sensitive : B
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
AR splice variant 7 negative	Prostate Cancer	AR splice variant 7 negative	Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Estrogen Receptor Positive Breast Cancer	AR positive	Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2